Compare
Lemaitre Vascular Inc vs Iradimed Corp vs Embecta Corp. vs Utah Medical Products Inc
| Latest fiscal year | Lemaitre Vascular Inc LMAT | Iradimed Corp IRMD | Embecta Corp. EMBC | Utah Medical Products Inc UTMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $249.60M | $83.81M | $1.08B | $38.52M |
| Revenue growth (YoY) | +13.5% | +14.4% | -3.8% | -5.8% |
| Gross margin | 71.5% | 76.7% | 62.6% | 57.1% |
| Operating margin | 27.2% | 31.2% | 22.4% | 29.6% |
| Net margin | 23.1% | 26.8% | 8.8% | 29.3% |
| Net income | $57.73M | $22.48M | $95.40M | $11.29M |
| EPS (Diluted) | $2.52 | $1.75 | $1.62 | $3.48 |
| Operating cash flow | $81.25M | $24.95M | $191.70M | $14.69M |
| Free cash flow | $74.47M | $17.18M | $182.40M | $14.32M |
| Cash & equivalents | $28.24M | $51.16M | $225.50M | $85.76M |
| Total assets | $615.69M | $108.78M | $1.09B | $122.54M |
| Total liabilities | $222.17M | $14.16M | n/a | $3.27M |
| Shareholders' equity | $393.52M | $94.62M | -$650.60M | $119.27M |
| Return on year-end equity | 14.7% | 23.8% | n/a | 9.5% |
| Shares outstanding | 22.77M | 12.78M | 58.50M | 3.19M |
Revenue, most recent five fiscal years
| Fiscal year | Lemaitre Vascular Inc | Iradimed Corp | Embecta Corp. | Utah Medical Products Inc |
|---|---|---|---|---|
| Latest | $249.60M Ended 2025-12-31 | $83.81M Ended 2025-12-31 | $1.08B Ended 2025-09-30 | $38.52M Ended 2025-12-31 |
| 1 year earlier | $219.86M Ended 2024-12-31 | $73.24M Ended 2024-12-31 | $1.12B Ended 2024-09-30 | $40.90M Ended 2024-12-31 |
| 2 years earlier | $193.48M Ended 2023-12-31 | $65.56M Ended 2023-12-31 | $1.12B Ended 2023-09-30 | $50.22M Ended 2023-12-31 |
| 3 years earlier | $161.65M Ended 2022-12-31 | $53.30M Ended 2022-12-31 | $1.13B Ended 2022-09-30 | $52.28M Ended 2022-12-31 |
| 4 years earlier | $154.42M Ended 2021-12-31 | $41.81M Ended 2021-12-31 | $1.17B Ended 2021-09-30 | $49.05M Ended 2021-12-31 |